Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAKAB1626

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	AUG 10	Time limit for inactive STN sessions doubles to 40 minutes
NEWS 3	AUG 18	COMPENDEX indexing changed for the Corporate Source (CS) field
NEWS 4	AUG 24	ENCOMPLIT/ENCOMPLIT2 reloaded and enhanced
NEWS 5	AUG 24	CA/CAplus enhanced with legal status information for U.S. patents
NEWS 6	SEP 09	50 Millionth Unique Chemical Substance Recorded in CAS REGISTRY
NEWS 7	SEP 11	WPIDS, WPINDEX, and WPIX now include Japanese FTERM thesaurus
NEWS 8	OCT 21	Derwent World Patents Index Coverage of Indian and Taiwanese Content Expanded
NEWS 9	OCT 21	Derwent World Patents Index enhanced with human translated claims for Chinese Applications and Utility Models
NEWS 10	NOV 23	Addition of SCAN format to selected STN databases
NEWS 11	NOV 23	Annual Reload of IFI Databases
NEWS 12	DEC 01	FRFULL Content and Search Enhancements
NEWS 13	DEC 01	DGENE, USGENE, and PCTGEN: new percent identity feature for sorting BLAST answer sets
NEWS 14	DEC 02	Derwent World Patent Index: Japanese FI-TERM thesaurus added
NEWS 15	DEC 02	PCTGEN enhanced with patent family and legal status display data from INPADOCDB
NEWS 16	DEC 02	USGENE: Enhanced coverage of bibliographic and sequence information
NEWS 17	DEC 21	New Indicator Identifies Multiple Basic Patent Records Containing Equivalent Chemical Indexing in CA/CAplus
NEWS 18	JAN 12	Match STN Content and Features to Your Information Needs, Quickly and Conveniently

NEWS EXPRESS MAY 26 09 CURRENT WINDOWS VERSION IS V8.4,
AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:48:53 ON 20 JAN 2010

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.22	0.22

FILE 'REGISTRY' ENTERED AT 12:49:06 ON 20 JAN 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 19 JAN 2010 HIGHEST RN 1202629-39-7
DICTIONARY FILE UPDATES: 19 JAN 2010 HIGHEST RN 1202629-39-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\STNEXP\Queries\10595892 A is N.str



chain nodes :
10 12 13 14 15 16
ring nodes :

```
1  2  3  4  5  6  7  8  9
chain bonds :
2-9  8-10  10-12  10-13  14-15  15-16
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  7-8  7-9  8-9
exact/norm bonds :
7-8  7-9  8-9  10-12  10-13  14-15  15-16
exact bonds :
2-9  8-10
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6


G1:O,S

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:CLASS
12:CLASS  13:CLASS  14:CLASS  15:CLASS  16:Atom  19:Atom



L1      STRUCTURE UPLOADED

=> d L1
L1 HAS NO ANSWERS
L1              STR
```




```
 G1 O,S



Structure attributes must be viewed using STN Express query preparation.


=> s L1 SSS SAM
SAMPLE SEARCH INITIATED 12:49:25 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     4905 TO ITERATE

 40.8% PROCESSED     2000 ITERATIONS                                 1 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        93900 TO   102300
PROJECTED ANSWERS:               1 TO      142

L2            1 SEA SSS SAM L1

=> s L1 SSS full
THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 191.05 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
```

FULL SEARCH INITIATED 12:49:38 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 98212 TO ITERATE

100.0% PROCESSED 98212 ITERATIONS 30 ANSWERS
SEARCH TIME: 00.00.08

L3 30 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 191.54 191.76

FILE 'CAPLUS' ENTERED AT 12:49:50 ON 20 JAN 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 20 Jan 2010 VOL 152 ISS 4
FILE LAST UPDATED: 19 Jan 2010 (20100119/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Oct 2009

CAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3 SSS full
L4 4 L3

=> d ibib abs hitstr 1-
YOU HAVE REQUESTED DATA FROM 4 ANSWERS - CONTINUE? Y/(N):y

L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2008:1389298 CAPLUS Full-text
DOCUMENT NUMBER: 150:121210
TITLE: One-pot approach for the synthesis of trans-cyclopropyl compounds from aldehydes. Application to the synthesis of GPR40 receptor agonists
AUTHOR(S): Davi, Michael; Lebel, Helene
CORPORATE SOURCE: Departement de Chimie, Universite de Montreal, Montreal, QC, H3T 1J4, Can.

SOURCE: Chemical Communications (Cambridge, United Kingdom) (2008), (40), 4974-4976
CODEN: CHCOFS; ISSN: 1359-7345
PUBLISHER: Royal Society of Chemistry
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 150:121210

AB Trans-2-arylcyclopropane-1-carboxylates were prepared in a novel multicatalytic one-pot process from aldehydes and diazomethane derivs. This process was applied to the synthesis of 3-phenoxybenzylaminophenylcyclopropanecarboxylates as GPR40 small mol. agonists.

IT 1097207-90-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of trans-2-arylcyclopropane-1-carboxylates, including GPR40 agonists, from aldehydes)

RN 1097207-90-3 CAPLUS

CN Cyclopropanecarboxamide, N,N-dimethyl-2-[4-[[(3-phenoxyphenyl)methyl]amino]phenyl]-, (1R,2R)-rel- (CA INDEX NAME)

Relative stereochemistry.



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2006:188876 CAPLUS Full-text
DOCUMENT NUMBER: 144:432528
TITLE: Synthesis and activity of small molecule GPR40 agonists
AUTHOR(S): Garrido, Dulce M.; Corbett, David F.; Dwornik, Kate A.; Goetz, Aaron S.; Littleton, Thomas R.; McKeown, Steve C.; Mills, Wendy Y.; Smalley, Terrence L.; Briscoe, Celia P.; Peat, Andrew J.
CORPORATE SOURCE: GlaxoSmithKline Research and Development, Research Triangle Park, NC, 27709, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2006), 16(7), 1840-1845
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 144:432528

AB The identification and structure-activity relationships of a novel series of GPR40 agonists based on a 3-(4-{[N-alkyl]amino}phenyl)propanoic acid template is described. Structural modifications to the original screening hit yielded compds. with a 100-fold increase in potency at the human GPR40 receptor and pEC50s in the low nanomolar range. The carboxylic acid moiety is not critical

for activity but typically elicits an agonistic response higher than those observed with carboxamide replacements. These compds. may prove useful in unraveling the therapeutic potential of this receptor for the treatment of Type 2 diabetes.

IT 853403-61-9P 853403-63-1P 853403-64-2P
853403-66-4P 853403-67-5P 885102-17-0P
885102-20-5P 885102-21-6P 885102-22-7P
886450-37-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and activity of alkylaminophenylpropanoic acids as GPR40 agonists)

RN 853403-61-9 CAPLUS
CN Cyclopropanecarboxamide, 2-[4-[[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]methyl]amino]phenyl]-, (1R,2R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 853403-63-1 CAPLUS
CN Cyclopropanecarboxamide, N-hydroxy-2-[4-[[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]methyl]amino]phenyl]-, (1R,2R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 853403-64-2 CAPLUS
CN Cyclopropanecarboxamide, N-cyclobutyl-2-[4-[[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]methyl]amino]phenyl]-, (1S,2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 853403-66-4 CAPLUS
CN Cyclopropanecarboxamide, N-(1-methylethyl)-2-[4-[[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]methyl]amino]phenyl]-, (1R,2R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 853403-67-5 CAPLUS
CN Cyclopropanecarboxamide, N,N-dimethyl-2-[4-[[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]methyl]amino]phenyl]-, (1R,2R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 885102-17-0 CAPLUS
CN Cyclopropanecarboxamide, N-(1-methylethyl)-2-[4-[[(3-phenoxyphenyl)methyl]amino]phenyl]-, (1R,2R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 885102-20-5 CAPLUS
CN Cyclopropanecarboxamide, 2-[4-[[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]methyl]amino]phenyl]-N-[(1R)-1-phenylethyl]-, (1S,2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 885102-21-6 CAPLUS
CN Cyclopropanecarboxamide, 2-[4-[[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]methyl]amino]phenyl]-N-3-pyrrolidinyl-, (1S,2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 885102-22-7 CAPLUS
CN Cyclopropanecarboxamide, N-hydroxy-2-[4-[[(3-phenoxyphenyl)methyl]amino]phenyl]-, (1S,2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 886450-37-9 CAPLUS
CN Cyclopropanecarboxamide, N-(1-methylethyl)-2-[4-[[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]methyl]amino]phenyl]-, (1S,2S)- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 30 THERE ARE 30 CAPLUS RECORDS THAT CITE THIS RECORD (30 CITINGS)
REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2005:564633 CAPLUS Full-text
DOCUMENT NUMBER: 143:97110
TITLE: Preparation of cyclopropane amine derivatives as aggrecanase and MMP inhibitors
INVENTOR(S): Fryer, Andrew M.; Shiozaki, Makoto; Littmann, Nicole M.; Inaba, Takashi; Andrews, Steven W.; Yasue, Katsutaka; Laird, Ellen R.; Yokota, Masahiro; Haas, Julia; Imai, Hiroto; Maeda, Katsuya; Shinozaki, Yuichi; Hori, Yoshikazu
PATENT ASSIGNEE(S): Japan Tobacco Inc., Japan
SOURCE: PCT Int. Appl., 197 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005058808	A1	20050630	WO 2004-US41851	20041214

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,

NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG

AU 2004299454	A1	20050630	AU 2004-299454		20041214
CA 2549598	A1	20050630	CA 2004-2549598		20041214
EP 1694638	A1	20060830	EP 2004-814079		20041214
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU					
CN 1894206	A	20070110	CN 2004-80037396		20041214
JP 2007516981	T	20070628	JP 2006-545807		20041214
ZA 2006005247	A	20071031	ZA 2006-5247		20041214
US 20050222146	A1	20051006	US 2004-11781		20041215
IN 2006KN01460	A	20070504	IN 2006-KN1460		20060530
KR 2006109937	A	20061023	KR 2006-711851		20060615
US 20080242656	A1	20081002	US 2007-765136		20070619
PRIORITY APPLN. INFO.:			US 2003-529117P	P	20031215
			WO 2004-US41851	W	20041214
			US 2004-11781	B1	20041215

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): CASREACT 143:97110; MARPAT 143:97110
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R1 = -W-A-W1-A1; W = -(CH2)m-X-(CH2)n-; W1 = -(CH2)p-X1-(CH2)q-; m = 0-6; n = 0-6; p = 0-6; q = 0-6; X and X1 independently = linker such as single bond, alkylene group, alkenylene group, etc.; A = (un)substituted hydrocarbon ring or heterocycle; A1 = substituted hydrocarbon ring or heterocycle or A and A1 together may form (un)substituted hydrocarbon ring; R2 = -(CH2)p-X2-(CH2)q-A2, -(CH2)x-X2-(CH2)y-R8; X2 = linker such as -O-, -CO-, -COO-, etc.; A2 = (un)substituted hydrocarbon ring or heterocycle; x = 0-6; y = 0-6; R8 = H, halo, OH, etc.; R3 and R4 independently = -(CH2)x-X3-(CH2)y-A3, -(CH2)x-X4-(CH2)y-R9; X3 = linker such as -OCO-, alkynylene group, single bond, etc.; A3 = (un)substituted hydrocarbon ring or heterocycle; R9 = NO2, CN, NH2, etc.; X4 = linker such as single bond, alkylene group, alkenylene group, etc.; R5 = SH, -CH2SH, -CH2OH, etc.; R6 and R7 independently = -(CH2)x-X5-(CH2)y-A4; -(CH2)x-X6-(CH2)y-R10; X5 = linker such as alkylene group, -O-, -CO-, etc.; A4 = (un)substituted hydrocarbon ring or heterocycle; X6 = linker such as -OCO-, -COO-, single bond, etc.; R10 = NO2, CN, NH2, etc.] and their pharmaceutically acceptable salts, are prepared and disclosed as inhibitors of aggrecanase and MMP. Thus, e.g., II was prepared by deprotection of com. available (1R,2S)-1-tert-butoxycarbonylamino-2-phenylcyclopropanecarboxylic acid and subsequent coupling with 4-chlorobiphenylsulfonic acid chloride followed by esterification/alkylation/hydrolysis sequence. The activity of I to inhibit aggrecanase and MMP was evaluated using particle assay and fluorescence assay, resp., and it was revealed that compds. of the invention displayed IC50 values in the range of less than 0.1 μM up to not less than 10 μM in both assays. I as inhibitor of aggrecanase and MMP should prove useful in the treatment of osteoarthritis and rheumatoid arthritis. Pharmaceutical compns. comprising I are disclosed.

IT 856431-41-9P 856432-21-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of cyclopropane amine derivs. as aggrecanase and MMP inhibitors)

RN 856431-41-9 CAPLUS

CN Benzoic acid, 3-[[[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl][(1R,2S)-1-[(methylamino)carbonyl]-2-[3-[[2-(1-piperidinyl)ethyl]amino]phenyl]cyclopropyl]amino]methyl]-, hydrochloride (1:1), rel- (CA INDEX NAME)

Relative stereochemistry.



RN 856432-21-8 CAPLUS

CN Benzoic acid, 3-[[[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl][(1R,2S)-1-[(methylamino)carbonyl]-2-[3-[[2-(1-piperidinyl)ethyl]amino]phenyl]cyclopropyl]amino]methyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



IT 1044767-04-5

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of cyclopropane amine derivs. as aggrecanase and MMP inhibitors)

RN 1044767-04-5 CAPLUS

CN Benzoic acid, 3-[[[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl][(1R,2S)-1-

[(methylamino)carbonyl]-2-[3-[[2-(1-piperidinyl)ethyl]amino]phenyl]cyclopropyl]amino]methyl]-, methyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2005:493575 CAPLUS Full-text
DOCUMENT NUMBER: 143:43685
TITLE: Preparation of aminophenylcyclopropylcarboxylates as G protein coupled receptor 40 (GPR40) agonists.
INVENTOR(S): Corbett, David Francis; Dwornik, Kate Anna; Garrido, Dulce Maria; McKeown, Stephen Carl; Mills, Wendy Yoon; Peat, Andrew James; Smalley, Terrence Lee, Jr.
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 88 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2005051890	A1	20050609	WO 2004-US38126		20041115
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
US 20090105257	A1	20090423	US 2008-595892		20081029
PRIORITY APPLN. INFO.:			US 2003-523532P	P	20031119
			WO 2004-US38126	W	20041115

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 143:43685; MARPAT 143:43685
GI



I

AB Title compds. [I; n = 0-4; R1 = alkyl, alkoxy, halo, haloalkyl, NO2, cyano, NR7R8; R5, R7, R8 = H, alkyl; A = OH, NR2R3; R2, R3 = H, (Q1)qR4; q = 0-2; Q1 = alkylene; R4 = alkyl, haloalkyl, aryl, heteroaryl, cycloalkyl, heterocyclyl, OH, alkoxy, aryloxy; X1 = NH; X2 = C(R5)2; Y = aryl, heteroaryl; Z = (Q2)mR6; m = 0, 1; Q2 = NR5, O, S, O(CH2)p, CH2; p = 1-3; R6 = aryl, heteroaryl], were prepared Thus, trans-2-(4-aminophenyl)cyclopropanecarboxylic acid (preparation given) was refluxed with 3-phenoxybenzaldehyde in dichloroethane. The mixture was cooled to room temperature and treated with NaB(OAc)3H followed by stirring for 1 h to give 16% trans-2-[4-[[3-(phenoxy)phenyl]methyl]amino]cyclopropanecarboxylic acid trifluoroacetate. The latter showed pEC50 = 7.9 in a GPR40 SAR primary assay.

IT 853403-58-4P 853403-59-5P 853403-60-8P
853403-61-9P 853403-62-0P 853403-64-2P
853403-66-4P 853403-67-5P 853403-68-6P
853403-69-7P 853403-70-0P 853403-71-1P
853403-72-2P 853403-73-3P 853403-74-4P
885123-21-7P 886450-36-8P 886450-37-9P
886451-10-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compound; preparation of aminophenylcyclopropylcarboxylates as GPR40
agonists)

RN 853403-58-4 CAPLUS
CN Cyclopropanecarboxamide, 2-[4-[([1,1'-biphenyl]-4-ylmethyl)amino]phenyl]-, (1R,2R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 853403-59-5 CAPLUS
CN Cyclopropanecarboxamide, 2-[4-[[[4-(2-pyridinyl)phenyl]methyl]amino]phenyl]-, (1R,2R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 853403-60-8 CAPLUS
CN Cyclopropanecarboxamide, 2-[4-[[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]methyl]amino]phenyl]-N-(4-pyridinylmethyl)-, (1R,2R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 853403-61-9 CAPLUS
CN Cyclopropanecarboxamide, 2-[4-[[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]methyl]amino]phenyl]-, (1R,2R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 853403-62-0 CAPLUS
CN Cyclopropanecarboxamide, 2-[4-[[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]methyl]amino]phenyl]-N-(1-phenylethyl)-, (1S,2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 853403-64-2 CAPLUS
CN Cyclopropanecarboxamide, N-cyclobutyl-2-[4-[[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]methyl]amino]phenyl]-, (1S,2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 853403-66-4 CAPLUS
CN Cyclopropanecarboxamide, N-(1-methylethyl)-2-[4-[[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]methyl]amino]phenyl]-, (1R,2R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 853403-67-5 CAPLUS
CN Cyclopropanecarboxamide, N,N-dimethyl-2-[4-[[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]methyl]amino]phenyl]-, (1R,2R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 853403-68-6 CAPLUS
CN Cyclopropanecarboxamide, 2-[4-[[(3-phenoxyphenyl)methyl]amino]phenyl]-N-(4-pyridinylmethyl)-, (1R,2R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 853403-69-7 CAPLUS
CN Cyclopropanecarboxamide, N-[(4-methoxyphenyl)methyl]-2-[4-[[(3-phenoxyphenyl)methyl]amino]phenyl]-, (1R,2R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 853403-70-0 CAPLUS
CN Cyclopropanecarboxamide, 2-[4-[[(3-phenoxyphenyl)methyl]amino]phenyl]-N-[[4-(trifluoromethyl)phenyl]methyl]-, (1R,2R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 853403-71-1 CAPLUS
CN Cyclopropanecarboxamide, N-[2-(4-morpholinyl)ethyl]-2-[4-[[(3-phenoxyphenyl)methyl]amino]phenyl]-, (1R,2R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 853403-72-2 CAPLUS
CN Cyclopropanecarboxamide, 2-[4-[[(3-phenoxyphenyl)methyl]amino]phenyl]-N-(2,2,2-trifluoroethyl)-, (1R,2R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 853403-73-3 CAPLUS
CN Cyclopropanecarboxamide, N-(1-methylethyl)-2-[4-[[[4-(1-methylethyl)-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]methyl]amino]phenyl]-, (1R,2R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 853403-74-4 CAPLUS
CN Cyclopropanecarboxamide, N-(cyclopropylmethyl)-2-[4-[[(3-phenoxyphenyl)methyl]amino]phenyl]-, (1S,2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 885123-21-7 CAPLUS
CN Cyclopropanecarboxamide, N-(1-methylethyl)-2-[4-[[(3-phenoxyphenyl)methyl]amino]phenyl]-, (1S,2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 886450-36-8 CAPLUS
CN Cyclopropanecarboxamide, 2-[4-[[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]methyl]amino]phenyl]-, (1S,2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 886450-37-9 CAPLUS
CN Cyclopropanecarboxamide, N-(1-methylethyl)-2-[4-[[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]methyl]amino]phenyl]-, (1S,2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 886451-10-1 CAPLUS
CN Cyclopropanecarboxamide, N-hydroxy-2-[4-[[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]methyl]amino]phenyl]-, (1S,2S)- (CA INDEX NAME)

Absolute stereochemistry.



IT 853403-97-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aminophenylcyclopropylcarboxylates as GPR40 agonists)
RN 853403-97-1 CAPLUS
CN Cyclopropanecarboxamide, 2-[4-[[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]methyl]amino]phenyl]-N-(4-pyridinylmethyl)-, (1R,2R)-rel-,

2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 886577-88-4
CMF C28 H25 F3 N4 O S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (7 CITINGS)
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log off
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y
STN INTERNATIONAL LOGOFF AT 12:50:12 ON 20 JAN 2010